DMPS is registered in Germany since 1997 under the name Dimaval (Heyl, Berlin). It was registered under the same name Dimaval in Taiwan in 2002.
It is available in capsule form for oral treatment (1 capsule contains 100mg), and as 5ml ampules (250mg) for intravenous application (IV or IM).
DMPS is routinely used in clinical practice as a chelating agent of heavy metals, and is highly effective for the binding and elimination of arsenic, mercury and lead.
Successful clinical trials have been conducted in Germany, the USA (University of Rochester), the Iraq, Bangladesh and the Philippines.
For more information, contact Dr. Ruprecht of Heyl, Berlin firstname.lastname@example.org
The type of antidote, dose, administration and urine collection must be determined through clinical evaluation and the type and severity of the intoxication.
For the treatment of chronic exposures, provocation test results aid in assessing the treatment duration.
Indication: Chronic mercury or other metal intoxication
Contraindication: Reduced kidney function (Serum Creatinin > 2.5 mg/dl) Hypersensitivity for DMPS (see product information.) Special precautions must be taken with allergy or asthma patients.
 VanderSchaar P. Textbook of Clinical Metal Toxicology, IBCMT (2012).